Is Banking of HLA-typed iPS Cell Lines for Cell-Based Therapy Practical, Sustainable and Commercially Feasible?
The first pilot clinical study of cell-based therapy using human induced pluripotent stem cell (iPSC) has started in Japan, and banking of HLA-typed iPSC lines is proposed for practical application of the iPSC-based therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.